863 related articles for article (PubMed ID: 24758886)
1. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
Latourte A; Bardin T; Richette P
Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Schlesinger N
Semin Arthritis Rheum; 2012 Oct; 42(2):155-65. PubMed ID: 22542277
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
5. [Gout management: an update].
Ankli B; Krähenbühl S
Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
[TBL] [Abstract][Full Text] [Related]
6. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
[TBL] [Abstract][Full Text] [Related]
7. Casebook consults: improving outcomes in gout (multimedia activity).
Doghramji PP; Mandell BF; Pope RS
Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
[TBL] [Abstract][Full Text] [Related]
8. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
[TBL] [Abstract][Full Text] [Related]
9. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
11. Current and future therapies for gout.
Pascart T; Richette P
Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
[TBL] [Abstract][Full Text] [Related]
12. Gout--what are the treatment options?
Schlesinger N; Dalbeth N; Perez-Ruiz F
Expert Opin Pharmacother; 2009 Jun; 10(8):1319-28. PubMed ID: 19463070
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
16. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
George M; Pullman-Mooar S; Hussain F; Schumacher HR
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
[TBL] [Abstract][Full Text] [Related]
17. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Bakris GL; Doghramji PP; Keenan RT; Silber SH
Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
[TBL] [Abstract][Full Text] [Related]
18. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs.
Peterson DM
J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):402-4. PubMed ID: 21133751
[TBL] [Abstract][Full Text] [Related]
20. Association between the initial dose urate-lowering drugs and gout flares in adult males with gout.
Li X; Shao Q; Shen J; Ren S; Li L; Lu H; Chen S
Rheumatology (Oxford); 2024 May; 63(6):1599-1606. PubMed ID: 37610331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]